Chief of Thoracic Oncology, MSKCC
New York, NY
Joined June 2014
- Tweets 183
- Following 227
- Followers 2,064
- Likes 285
Charlie Rudin retweeted
1 Hot off the press from team @MSKCancerCenter in @CD_AACR!
A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC
This took nearly a decade and 42 coauthors to unravel.
Here are some highlights 👇
aacrjournals.org/cancerdisco…
Charlie Rudin retweeted
Now online in @CD_AACR: #Chromothripsis-mediated Small Cell Lung Carcinoma - by @natasharekhtman @SamTTweets @ChrisFebres @charlesrudin and colleagues doi.org/10.1158/2159-8290.CD… @MSKCancerCenter #SCLC
Charlie Rudin retweeted
Inspiration for the August cover art:
First-in-human trial of #imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade #neuroendocrinetumours of the lung and prostate thelancet.com/journals/lanon…
#NeuroendocrineTumors #SCLC
Charlie Rudin retweeted
So excited, our phase 1/2 first in human imaging w/ [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate, is out. JT Poirier @charlesrudin @LewisLabMSKCC @Tendler_S @morr316 @lisabodei et al., sciencedirect.com/science/ar…
with particularly striking declines in incidence and death rates among those under age 50... a harbinger, perhaps. Still much to do!
Are we heading toward a future where #lungcancer is NOT the leading cause of US cancer mortality in either men or women? Data out today in doi.org/10.3322/caac.21820 continuing a nice trend --
DLL3 is the target of multiple investigational therapeutic strategies for patients with SCLC and other high-grade NE cancers. A pleasure to review state-of-the-state together with many clinical leaders of the field. jhoonline.biomedcentral.com/…
A brief reflection on the exceptional fertility of graveyards...(!) Thanks to @NatureCancer and editor @LisaHass0107 for the invitation, and to @MSKCancerCenter and @HopkinsMedicine for supporting the freedom to explore. rdcu.be/dcZQv
Why aren’t most small cell lung cancers more responsive to immunotherapy? Epigenetic silencing of antigen presentation might be one key — and targetable — solution. Data from BMS CheckMate 032. jto.org/article/S1556-0864(2…
Charlie Rudin retweeted
Happy to see our work on CD39+ CD8+ T cells in human lung cancer being profiled by @EACRnews ! @charlesrudin @wolchokj @merghout @MSKCancerCenter
Read our May edition of Highlights in Cancer Research, a summary of the most interesting and impactful recent papers in cancer research, curated by the EACR Board:
magazine.eacr.org/highlights…
Is sciencetwitter still a thing? Maybe... Really happy to see this one out in press; the very talented Janneke Jaspers demonstrates efficacy of an anti-DLL3 IL-18-armored CAR-T against small cell lung cancer. jci.org/articles/view/166028
Charlie Rudin retweeted
🎉 Join @charlesrudin & @LealTiciana for the FIRST ANNUAL #SCLCYIF, in collaboration w/ @LUNGevity!🔬
Improve your research skills, evaluate peers' work & enhance your career as an #SCLC researcher!
Submit Abstracts by May 19➡️➡️➡️ ce.ceconcepts.com/sclc-23
#Oncology #MedTwitter
Pts with EGFR-mutant lung CA rarely benefit from immunoRX. But for those who want, without giving up TKI — combo with erlotinib (NOT osi!) appears feasible. I have at least one patient who started on this in 2014, still responding. Every pt is an N of 1! authors.elsevier.com/sd/arti…
Out today — great work defining the role of CD39+ CD8 T cells in anti-cancer immunity led by @AndrewChowMDPhD with key support from @merghout, Jedd Wolchok, and many others. authors.elsevier.com/a/1gJgV…
Also great thanks to the apparently twitter-free David Killock for editorial assistance @NatRevClinOncol
New review on neuroendocrine cancers across sites of origin, with a particular focus on lung and GI, led by post-doc @Kenta_Oncology, and with key contributions by @natasharekhtman and @AlvaroQuintanal! @MSKCancerCenter rdcu.be/cYsMF
Charlie Rudin retweeted
ICYMI at #WCLC22: Presenters discussed optimizing the management of SCLC and neuroendocrine tumors. Read a recap in ILCN: ow.ly/RZO650KLuG7 @alvaroquintanal #LCSM
EVERY week should be post-doc appreciation week – but here it is. Some of this crew is beyond post-doc, on faculty, but included here as essential to the functioning of our lab. Thank you all for all you do! @MSKEducation
Charlie Rudin retweeted
APOBEC, a prominent mutational signature in oncogenesis, initiates from the activity of the A3A & A3B cytosine deaminases.
In this original article, investigators studied its association with RTK-driven lung cancer 🫁 including resistance to treatments💊
annalsofoncology.org/article…
